Sermorelin, a synthetic analog of growth hormone–releasing hormone (GHRH 1–29), has long attracted scientific interest due to ...
New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...
Hormones control essential processes like growth, metabolism, mood, and reproduction, but when their balance is disrupted, it ...
Stefan Bornstein, MD, PhD, professor, made it clear during a press conference at the 67th Congress of the German Society of Endocrinology (DGE) that there is more than one interaction between them.
In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...
Pregnancy complications such as preeclampsia, fetal growth restriction (FGR), gestational diabetes, and hypertensive ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
An analysis of 12-year results from the C9741 breast cancer trial confirmed the benefit of dose-dense versus conventional chemotherapy for patients with node-positive disease, but also showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results